FCER2 and B-cell chronic lymphocytic leukemia: CXCL13 and CCL19 together can inhibit the TNFα-mediated apoptosis of the CD23+ CD5+ B cell lineage, which is the commonest malignant cell type in acute and chronic lymphocytic leukemia [40].